KPC Pharmaceuticals (SHSE:600422) Total Equity: ¥6,798 Mil (As of Mar. 2026)


SHSE:600422 KPC Pharmaceuticals Inc SHSE:600422
62 GF Score
Price ¥8.28
GF Value ¥11.90
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is KPC Pharmaceuticals Total Equity?

KPC Pharmaceuticals SHSE:600422 +1.85% 62 Total Equity is ¥6,798 Mil as of Mar. 2026. GuruFocus rates SHSE:600422 with a GF Score™ of 62/100 and a GF Value™ of ¥11.90 (Significantly Undervalued). The stock has 7 warning signs investors should review.

KPC Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was ¥6,798 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

KPC Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for KPC Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KPC Pharmaceuticals Total Equity Chart

KPC Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,940.32 5,142.52 7,954.43 6,746.27 6,941.41

KPC Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,861.10 6,771.08 6,855.72 6,941.41 6,797.55
SHSE:600422
62GF Score
KPC Pharmaceuticals Inc SHSE:600422
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KPC Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

KPC Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=11773.564-4832.16
=6,941

KPC Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11215.403-4417.856
=6,798

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ¥6,798 Mil mean?
KPC Pharmaceuticals (SHSE:600422) has a Total Equity of ¥6,798 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for KPC Pharmaceuticals and its competitors.
Is KPC Pharmaceuticals' Total Equity too high?
KPC Pharmaceuticals' current Total Equity is ¥6,798 Mil. Overall, KPC Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' Total Equity compare to ZTS and UTHR?
KPC Pharmaceuticals' Total Equity of ¥6,798 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for KPC Pharmaceuticals and its competitors. KPC Pharmaceuticals's current Total Equity is ¥6,798 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥11.90, compared to a current price of ¥8.28 — trading 30.4% below its estimated fair value. The current Total Equity is ¥6,798 Mil. KPC Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current Total Equity is ¥6,798 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?

Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued. The current stock price of ¥8.28 is trading 30.4% below its estimated GF Value™ of ¥11.90. GuruFocus considers KPC Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for SHSE:600422:

  • Total Equity: ¥6,798 Mil
  • GF Value™: ¥11.90 vs. price of ¥8.28 (30.4% below fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KPC Pharmaceuticals Business Description

Address No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
62GF Score

Get the complete analysis for SHSE:600422

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.28
Price
¥11.90
GF Value